TY - JOUR
T1 - International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells
T2 - considerations for potential therapeutic agents to suppress coronavirus disease-19
AU - Börger, Verena
AU - Weiss, Daniel J.
AU - Anderson, Johnathon D.
AU - Borràs, Francesc E.
AU - Bussolati, Benedetta
AU - Carter, David R.F.
AU - Dominici, Massimo
AU - Falcón-Pérez, Juan M.
AU - Gimona, Mario
AU - Hill, Andrew F.
AU - Hoffman, Andrew M.
AU - de Kleijn, Dominique
AU - Levine, Bruce L.
AU - Lim, Rebecca
AU - Lötvall, Jan
AU - Mitsialis, S. Alex
AU - Monguió-Tortajada, Marta
AU - Muraca, Maurizio
AU - Nieuwland, Rienk
AU - Nowocin, Anna
AU - O'Driscoll, Lorraine
AU - Ortiz, Luis A.
AU - Phinney, Donald G.
AU - Reischl, Ilona
AU - Rohde, Eva
AU - Sanzenbacher, Ralf
AU - Théry, Clotilde
AU - Toh, Wei Seong
AU - Witwer, Kenneth W.
AU - Lim, Sai Kiang
AU - Giebel, Bernd
N1 - Publisher Copyright:
© 2020 International Society for Cell and Gene Therapy
PY - 2020/9
Y1 - 2020/9
N2 - STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.
AB - STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.
UR - http://www.scopus.com/inward/record.url?scp=85087294732&partnerID=8YFLogxK
U2 - 10.1016/j.jcyt.2020.05.002
DO - 10.1016/j.jcyt.2020.05.002
M3 - Artículo
C2 - 32425691
AN - SCOPUS:85087294732
SN - 1465-3249
VL - 22
SP - 482
EP - 485
JO - Cytotherapy
JF - Cytotherapy
IS - 9
ER -
